Terms: = Lymphoma AND PMS2, HNPCC4, 5395, ENSG00000122512, H_DJ0042M02_9, PMSL2, PMS2CL AND Treatment
2131 results:
1. Efficacy and safety of netupitant/palonosetron in preventing nausea and vomiting in diffuse large B cell lymphoma patients undergoing R-CHOP chemotherapy.
Kwak K; Park Y; Kim BS; Kang KW
Sci Rep; 2024 May; 14(1):11229. PubMed ID: 38755279
[TBL] [Abstract] [Full Text] [Related]
2. Associations Between Stress, Health Behaviors, and Quality of Life in Young Couples During the Transition to Survivorship: Protocol for a Measurement Burst Study.
Cho D; Roth M; Peterson SK; Jennings K; Kim S; Weathers SP; Ahmed S; Livingston JA; Barcenas C; You YN; Milbury K
JMIR Res Protoc; 2024 Apr; 13():e53307. PubMed ID: 38652520
[TBL] [Abstract] [Full Text] [Related]
3. Left atrial reservoir longitudinal strain and its incremental value to the left ventricular global longitudinal strain in predicting anthracycline-induced cardiotoxicity.
Li Z; Zhao R; Zhang Q; Shen Y; Shu X; Cheng L
Echocardiography; 2024 Apr; 41(4):e15805. PubMed ID: 38558436
[TBL] [Abstract] [Full Text] [Related]
4. Survival benefit in EGFR-wild and ALK negative NSCLC patients who participate in clinical trials compared to standard-of-care: Propensity-matched analysis.
Jung HA; Park B; Park S; Sun JM; Lee SH; Seok Ahn J; Ahn MJ
Lung Cancer; 2024 Apr; 190():107536. PubMed ID: 38493759
[TBL] [Abstract] [Full Text] [Related]
5. Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and MET exon 14 skipping in NSCLC.
Melchior L; Hirschmann A; Hofman P; Bontoux C; Concha A; Mrabet-Dahbi S; Vannuffel P; Watkin E; Putzová M; Scarpino S; Cayre A; Martin P; Stoehr R; Hartmann A
Virchows Arch; 2024 Apr; 484(4):677-686. PubMed ID: 38492039
[TBL] [Abstract] [Full Text] [Related]
6. Neutrophilic Dermatosis of the Hands: A Case Report.
Yaghoobi R; Bagherani N; R Smoller B; Pazyar N
Acta Dermatovenerol Croat; 2023 Dec; 31(3):148-50. PubMed ID: 38439725
[TBL] [Abstract] [Full Text] [Related]
7. Patient-Reported Outcomes and Mortality in Cutaneous Chronic Graft-vs-Host Disease.
Baumrin E; Shin DB; Mitra N; Pidala J; El Jurdi N; Lee SJ; Loren AW; Gelfand JM
JAMA Dermatol; 2024 Apr; 160(4):393-401. PubMed ID: 38416506
[TBL] [Abstract] [Full Text] [Related]
8. Case 322: Pyothorax-associated lymphoma.
Hu JY; Lee KH; Yun G
Radiology; 2024 Feb; 310(2):e223090. PubMed ID: 38411510
[TBL] [Abstract] [Full Text] [Related]
9. Pancreas-related persisting sequelae in ALL survivors with a history of asparaginase-associated pancreatitis: A part of the ALL-STAR study.
Skipper MT; Birkebæk N; Jensen RB; Rank CU; Tuckuviene R; Wehner PS; Lambine TL; Hørlyck A; Schmiegelow K; Frandsen TL; Andrés-Jensen L; Albertsen BK
Eur J Haematol; 2024 Jun; 112(6):944-956. PubMed ID: 38351310
[TBL] [Abstract] [Full Text] [Related]
10. Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.
Tam CS; Opat S; D'Sa S; Jurczak W; Lee HP; Cull G; Owen RG; Marlton P; Wahlin BE; García-Sanz R; McCarthy H; Mulligan S; Tedeschi A; Castillo JJ; Czyż J; Fernández De Larrea C; Belada D; Libby E; Matous J; Motta M; Siddiqi T; Tani M; Trněný M; Minnema MC; Buske C; Leblond V; Treon SP; Trotman J; Wu B; Yu Y; Shen Z; Chan WY; Schneider J; Allewelt H; Cohen A; Dimopoulos MA
Blood Adv; 2024 Apr; 8(7):1639-1650. PubMed ID: 38315878
[TBL] [Abstract] [Full Text] [Related]
11. Long-term outcomes with HLX01 (HanliKang
Qin Y; Song Y; Wang D; Bai O; Feng J; Sun X; Qiu L; Yang J; Yang Y; Wang Z; Hu J; Wang H; Su H; Jin Z; Qian W; Jin C; Zhang M; Yu D; Liu L; Chen G; Li Y; Sun T; Jin J; Bao H; Du X; Zhou H; Fu G; Shi Y
BMC Cancer; 2024 Jan; 24(1):124. PubMed ID: 38267866
[TBL] [Abstract] [Full Text] [Related]
12. A Multicenter Study of Needle Size and Safety for Splenic Biopsy.
Kavandi H; Itani M; Strnad B; Martin S; Ebrahimzadeh SA; Lubner MG; Noe-Kim V; Hinshaw JL; Bansal M; Karam AR; Khanna K; Hadied MO; Planz V; Glazer DI; Burgan CM; Galgano S; Brook A; Brook OR
Radiology; 2024 Jan; 310(1):e230453. PubMed ID: 38259204
[TBL] [Abstract] [Full Text] [Related]
13. Real-world Effectiveness of Azacitidine in treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes.
Rajakumaraswamy N; Gandhi M; Wei AH; Sallman DA; Daver NG; Mo S; Iqbal S; Karalliyadda R; Chen M; Wang Y; Vyas P
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):260-268.e2. PubMed ID: 38216397
[TBL] [Abstract] [Full Text] [Related]
14. PD-L1
Allbee AW; Gerson J; Yang G; Bagg A
Cold Spring Harb Mol Case Stud; 2023 Dec; 9(4):. PubMed ID: 38199780
[TBL] [Abstract] [Full Text] [Related]
15. [Prognostic factors in patients with hematological malignancies and concomitant chronic hepatitis C].
Nozhkin MS; Lioznov DA; Antonova TV; Gorchakova OV; Goldstein EM; Popova MO; Shneyder TV
Ter Arkh; 2023 Dec; 95(11):919-923. PubMed ID: 38158946
[TBL] [Abstract] [Full Text] [Related]
16. KTt-45, a T-type calcium channel blocker, acts as an anticancer agent by inducing apoptosis on HeLa cervical cancer cell line.
Du NH; Ngoc TTB; Cang HQ; Luyen NTT; Thuoc TL; Le Quan T; Thao DTP
Sci Rep; 2023 Dec; 13(1):22092. PubMed ID: 38086845
[TBL] [Abstract] [Full Text] [Related]
17. Ibrutinib Efficacy, Safety, and Pharmacokinetics in Chinese Patients with Relapsed or Refractory Waldenström's Macroglobulinemia: A Multicenter, Single-Arm, Phase 4 Study.
Yi S; Cai Z; Hu Y; He A; Gao S; Li Q; Sha L; Zhang N; Ren Y; Gai X; Yang X; Qin R; Qiu L
Adv Ther; 2024 Feb; 41(2):672-685. PubMed ID: 38079089
[TBL] [Abstract] [Full Text] [Related]
18. Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell lymphoma: Primary Analysis of the Mantle Cell lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study.
Wang M; Siddiqi T; Gordon LI; Kamdar M; Lunning M; Hirayama AV; Abramson JS; Arnason J; Ghosh N; Mehta A; Andreadis C; Solomon SR; Kostic A; Dehner C; Espinola R; Peng L; Ogasawara K; Chattin A; Eliason L; Palomba ML
J Clin Oncol; 2024 Apr; 42(10):1146-1157. PubMed ID: 38072625
[TBL] [Abstract] [Full Text] [Related]
19. Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial.
Al-Sawaf O; Ligtvoet R; Robrecht S; Stumpf J; Fink AM; Tausch E; Schneider C; Boettcher S; Mikusko M; Ritgen M; Schetelig J; von Tresckow J; Vehling-Kaiser U; Gaska T; Wendtner CM; Chapuy B; Fischer K; Kreuzer KA; Stilgenbauer S; Staber P; Niemann C; Hallek M; Eichhorst B
Nat Med; 2024 Jan; 30(1):240-248. PubMed ID: 38071379
[TBL] [Abstract] [Full Text] [Related]
20. Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial.
Zeidan AM; Ando K; Rauzy O; Turgut M; Wang MC; Cairoli R; Hou HA; Kwong YL; Arnan M; Meers S; Pullarkat V; Santini V; Malek K; Kiertsman F; Niolat J; Ramos PM; Menssen HD; Fenaux P; Miyazaki Y; Platzbecker U
Lancet Haematol; 2024 Jan; 11(1):e38-e50. PubMed ID: 38065203
[TBL] [Abstract] [Full Text] [Related]
[Next]
